Intravitreal Anti-vascular Endothelial Growth Factor for Treating Polypoidal Choroidal Vasculopathy with Grape-like Polyp Clusters.
10.3341/kjo.2016.30.4.272
- Author:
Young Suk CHANG
1
;
Jae Hui KIM
;
Jong Woo KIM
;
Tae Gon LEE
;
Chul Gu KIM
Author Information
1. Department of Ophthalmology, Konyang University College of Medicine, Daejeon, Korea.
- Publication Type:Observational Study ; Original Article
- Keywords:
Age-related macular degeneration;
Anti-vascular endothelial growth factor;
Choroidal neovascularization;
Polypoidal choroidal vasculopathy
- MeSH:
Aged;
Angiogenesis Inhibitors/*administration & dosage;
Choroid/blood supply/*diagnostic imaging;
Choroidal Neovascularization/diagnosis/*drug therapy;
Female;
Fluorescein Angiography;
Follow-Up Studies;
Fundus Oculi;
Humans;
Intravitreal Injections;
Male;
Polyps/diagnosis/*drug therapy;
Retrospective Studies;
Tomography, Optical Coherence;
Vascular Endothelial Growth Factor A/*antagonists & inhibitors
- From:Korean Journal of Ophthalmology
2016;30(4):272-279
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: To evaluate 12-month outcomes of anti-vascular endothelial growth factor (VEGF) therapy for polypoidal choroidal vasculopathy (PCV) with grape-like polyp clusters. METHODS: This retrospective observational study included 23 eyes of 23 patients who were newly diagnosed with PCV with grape-like polyp clusters, and who were subsequently treated with anti-VEGF monotherapy. The study compares the best-corrected visual acuity (BCVA) of the patients at diagnosis, at 3 months, and at 12 months after diagnosis. In addition, 12-month changes in BCVA values were compared between cases with subfoveal or juxtafoveal polyps and cases with extrafoveal polyps. RESULTS: The baseline, 3-month, and 12-month logarithm of the minimal angle of resolution BCVA was 0.62 ± 0.35, 0.50 ± 0.43, and 0.58 ± 0.48, respectively. Compared to the baseline, patient BCVA was not significantly different at 12 months after diagnosis (p = 0.764). Six eyes (26.1%) gained ≥0.2 logarithm of the minimal angle of resolution BCVA. In cases with subfoveal or juxtafoveal polyps, BCVA values at baseline and at 12 months after diagnosis were 0.66 ± 0.37 and 0.69 ± 0.53, respectively. In cases with extrafoveal polyps, the values were 0.54 ± 0.33 and 0.37 ± 0.31, respectively. Changes in BCVA values were significantly different between the two groups (p = 0.023). CONCLUSIONS: Although anti-VEGF therapy has favorable short-term efficacy for treating PCV with grape-like polyp clusters, long-term visual improvements are generally limited in the majority of afflicted eyes. The presence of subfoveal or juxtafoveal polyps may suggest unfavorable treatment outcomes.
